Key Takeaways
- J&J is attempting to block Samsung Bioepis and Sandoz from marketing a private-label Stelara (ustekinumab) biosimilar through a PBM in the US.
J&J has been refused an injunction as part of ongoing US litigation through which the Stelara (ustekinumab) originator is attempting...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?